Yoshida Hiroyuki, Shibata Hiroko, Izutsu Ken-Ichi, Goda Yukihiro
Division of Drugs, National Institute of Health Sciences.
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences.
Biol Pharm Bull. 2017;40(5):722-725. doi: 10.1248/bpb.b16-00904.
The current Japanese Ministry of Health Labour and Welfare (MHLW)'s Guideline for Bioequivalence Studies of Generic Products uses averaged dissolution rates for the assessment of dissolution similarity between test and reference formulations. This study clarifies how the application of model-independent multivariate confidence region procedure (Method B), described in the European Medical Agency and U.S. Food and Drug Administration guidelines, affects similarity outcomes obtained empirically from dissolution profiles with large variations in individual dissolution rates. Sixty-one datasets of dissolution profiles for immediate release, oral generic, and corresponding innovator products that showed large variation in individual dissolution rates in generic products were assessed on their similarity by using the f statistics defined in the MHLW guidelines (MHLW f method) and two different Method B procedures, including a bootstrap method applied with f statistics (BS method) and a multivariate analysis method using the Mahalanobis distance (MV method). The MHLW f and BS methods provided similar dissolution similarities between reference and generic products. Although a small difference in the similarity assessment may be due to the decrease in the lower confidence interval for expected f values derived from the large variation in individual dissolution rates, the MV method provided results different from those obtained through MHLW f and BS methods. Analysis of actual dissolution data for products with large individual variations would provide valuable information towards an enhanced understanding of these methods and their possible incorporation in the MHLW guidelines.
日本厚生劳动省(MHLW)现行的仿制药生物等效性研究指南使用平均溶出率来评估受试制剂和参比制剂之间的溶出相似性。本研究阐明了欧洲药品管理局和美国食品药品监督管理局指南中描述的非模型多变量置信区域程序(方法B)的应用如何影响从个体溶出率差异较大的溶出曲线中凭经验获得的相似性结果。通过使用MHLW指南中定义的f统计量(MHLW f方法)以及两种不同的方法B程序,包括应用f统计量的自抽样法(BS方法)和使用马氏距离的多变量分析法(MV方法),对61个速释口服仿制药及其相应创新药的溶出曲线数据集进行了相似性评估,这些数据集显示仿制药的个体溶出率差异较大。MHLW f方法和BS方法得出的参比制剂与仿制药之间的溶出相似性相近。虽然相似性评估中的微小差异可能是由于个体溶出率的较大差异导致预期f值的置信区间下限降低所致,但MV方法得出的结果与MHLW f方法和BS方法不同。对个体差异较大的产品的实际溶出数据进行分析,将为深入理解这些方法以及它们可能纳入MHLW指南提供有价值的信息。